RLN2 is a novel candidate, and preclinical studies show that it can impact the tumor microenvironment, immune cell infiltration, and extracellular matrix remodeling, potentially increasing the efficacy of immunotherapy. This evidence concerns the gene RLN2 and neoplasm.